The Latest
-
Adeline Kon/BioPharma Dive
Deep DiveBiotech M&A is accelerating. Track the deals that are happening here.
Incyte and Johnson & Johnson both acquired privately held biotech companies on Monday in a pair of deals that could be worth up to $3 billion combined.
Updated 2 hours ago -
Permission granted by Middlesex County
Sponsored by Middlesex CountyInnovation alone is no longer enough in biopharma
In biopharma, the next edge may come from the systems that turn discovery into scale.
-
Getty Images
Study data convince Lundbeck to push new migraine drug forward
A possible alternative to “anti-CGRP” medications, the drug didn’t meet some analysts’ expectations in mid-stage testing but still convinced Lundbeck to pursue further development.
-
Fintan Trimble via Getty Images
Generic drugmakers gain key victory in ‘skinny label’ patent case
The Supreme Court ruled that a knockoff version of Amarin’s Vascepa didn’t infringe on patents — a decision with far-reaching implications for the availability of generics.
-
ASCO / Nick Agro
ASCO ‘26: Bispecifics vs. ADCs, a ‘RAS’ revolution and a step change in prostate cancer
At the year’s biggest cancer meeting, a high-stakes clash between two popular drug classes erupted, and scientists made headway against a once-insurmountable foe.
-
Getty Images
News roundupOtsuka showcases kidney drug data; Pfizer cuts an AI deal
Voyxact helped preserve kidney function, but left an opening for competing IgAN drugs from Vera and Vertex. Elsewhere, Takeda’s alliance with Innovent paid early dividends and Axsome warded off generic competitors.
-
Jacob Bell/BioPharma Dive
Alnylam, Inceptive ink AI deal potentially worth $2B
The RNA-focused drugmaker says Inceptive's tools will help prioritize the best development options as well as speed up the research process.
-
Getty Images
Celcuity breast cancer drug misses ‘lofty’ expectations in ASCO-spotlighted trial
Gedatolisib could “establish a new standard of care” for PIK3CA-mutated breast cancer, an investigator said, but the results nonetheless appeared to disappoint investors.
-
Getty Images
Emerging biotechLilly, Ascidian link up in RNA exon editing pact
Worth as much as $1.9 billion, the deal directs Ascidian to help Lilly find potential drugs for genetically driven kidney diseases.
-
Adeline Kon/BioPharma Dive
Deep Dive // IPO windowBiotech IPOs are the industry’s lifeblood. Track how they’re performing.
Parabilis Medicines set terms for an IPO that, at as much as $475 million, would rank as the year’s second-largest new biotech stock offering.
Updated June 5, 2026 -
Getty Images
Emerging biotechA Spanish biotech banks $87M to make differentiated ADCs
Ona Therapeutics, a Barcelona-based drugmaker, is developing next-generation drugs it says could help patients with advanced forms of breast and colorectal cancers.
-
Getty Images
‘Unprecedented’ Revolution data point to paradigm shift in pancreatic cancer
Highly anticipated data presented at ASCO confirmed what’s been heralded as a medical breakthrough against a historically tough-to-treat tumor.
-
Getty Images
An ADC specialist sinks on safety concerns for blood cancer drug
Shares for ADC Therapeutics fell more than 50% after a Phase 3 trial observed a death rate that at least one analyst believes “may be difficult to accept for physicians, patients and regulators.”
-
Getty Images
Legend surges on early data for ‘in vivo’ lymphoma cell therapy
Initial findings show that the therapy reduced or eliminated disease signs in all recipients, sparking hopes that the treatment might be competitive with “ex vivo” medicines like Novartis’ Kymriah.
-
Getty Images
News roundup
NewLimit’s $435M megaround; Lilly’s busy dealmaking week
The anti-aging biotech has secured one of the year’s biggest venture fundings to bring its first drug into testing. Elsewhere, Lilly nabbed a “GLP-2” obesity drug and Praxis shares tumbled.
-
Getty Images
AbiVax falls as safety worries cloud ‘landmark’ immune drug results
A handful of cancer cases reported among treatment recipients overshadowed efficacy results analysts described as “best-in-disease” and sent shares down more than 30%.
-
ASCO / Nick Agro
At ASCO, Merck makes case for a ‘cornerstone’ cancer drug
Study results accrued so far are giving Merck greater conviction that the therapy, licensed from a China-based biotech, was worth placing into a sprawling Phase 3 program.
-
Getty Images
Fulcrum exploring a potential sale after FDA sidelined its sickle cell drug
Fulcrum’s setback is the latest in a series of stumbles for the developers of sickle cell medicines, among them Pfizer, Novartis and Intellia Therapeutics.
-
Scott Olson via Getty Images
Eli Lilly issues data sharing ultimatum to 340B hospitals
Select hospitals have refused to share data to prove they’re not double-dipping drug discounts, Lilly said. Hospitals, which have until Monday to comply, are urging the government to intervene.
-
Getty Images
Akeso, Summit drug extends survival in closely watched lung cancer trial
Though ivonescimab reduced the risk of death by one-third compared to chemotherapy in a China-based study, the total survival benefit of four months stirred debate and pressured company shares.
Updated June 1, 2026 -
Getty Images
Servier buys into muscular dystrophy with potentially $2.7B deal
The French drugmaker has agreed to acquire an experimental tablet from Edgewise Therapeutics that some bullish analysts say could eventually hit peak sales of over $2 billion.
-
Getty Images
Emerging biotechRallyBio tries again for reverse merger, this time with Avenzo
It's the second attempt for the rare disease company, which initially announced plans to merge with Candid Therapeutics before the immune drug developer was bought by UCB.
-
Getty Images
Bristol Myers unveils data for one of its next-gen blood cancer drugs
Called mezigdomide, the drug is one of two protein-degrading medicines Bristol Myers hopes to soon position as successors to its lucrative Revlimid franchise.
-
Ned Pagliarulo/BioPharma Dive
ASCO26: 5 data snapshots ahead of the year’s biggest cancer drug meeting
Clinical trial abstracts posted Thursday ahead of this year’s ASCO meeting gave a peek at anticipated datasets from Merck, BioNTech, Eli Lilly and Moderna.
-
Sarah Silbiger via Getty Images
Replimune takes third swing at cancer drug approval following ‘productive’ FDA talks
A twice-spurned therapy that’s been seen as one of the FDA’s more controversial recent rejections is getting a new chance following the resignation of former commissioner Marty Makary.
-
Getty Images
Trump administrationCan a chaotic FDA still deliver on faster drug development?
As leadership changes create more instability at the FDA, here’s what one former agency official thinks it will take to keep speedier drug approvals on track.
